Ann: AGM Chairman's Address and Investor Presentation, page-60

Here is a part summery or the price outlook for PIQ by Morgans in Sept last year. Nice to note the predicted share price of $2.42 is only for sales in the
US only.
I believe the sales will commence Texas, with a population of 30 million, lets hope Sonic will be flat out meeting orders.

Forecast and valuation update:
▪ We have increased our US test pricing assumptions to US$390 (from US$150)
and applied a fairly hefty market uptake handbrake until we get a strong feel for
coverage uptake. Our DCF valuation increases to A$2.42 (from A$1.66).
Investment view:
▪ We view PIQ as a highly promising opportunity in FY24 driven by several major
catalysts. These encompass the initial steps towards commercialisation, which
will not only establish a foundation for FY25 onwards, but also multiple
advancements in the clinical and regulatory spheres, enhancing the company's
pipeline. We value PIQ using a DCF methodology and we set our price target at
the same level of A$1.66 p/s. We maintain a Speculative Buy recommendation,
supported by a blend of exciting growth prospects and strategic developments.